Interius will join Kite's research team and establish a center of excellence in Philadelphia, focusing on advancing in vivo therapies that could transform cancer treatment.

This strategic move aligns with Gilead's broader goal to innovate in medicine and expand access to transformative treatments in oncology and beyond.

Overall, the acquisition is a long-term investment in scalable, off-the-shelf therapies that could reshape Kite’s role in oncology and gene therapy, with cautious optimism for investors.

The deal positions Kite to capitalize on the rapidly growing gene therapy market, projected to reach over $55 billion by 2034, and to gain a first-mover advantage in in vivo CAR-T therapies.

Interius's modular platform can adapt quickly across various diseases and manufacturing scales, potentially expanding access to advanced cell therapies for patients with rapidly progressing conditions.

Gilead's backing provides financial strength and operational support, aiding the scaling of Interius’s pipeline and reducing reliance on existing CAR-T products.

The $350 million investment is expected to impact Gilead's 2025 EPS by approximately $0.23 to $0.25, with the closing contingent on regulatory approvals and customary conditions.

Kite, a Gilead company, announced it will acquire Interius BioTherapeutics for $350 million to bolster its in vivo cell therapy platform, aiming to develop next-generation treatments.

This acquisition combines Interius's innovative platform with Kite's extensive expertise in cell therapy, potentially accelerating the availability of off-the-shelf, personalized therapies delivered via a single infusion.

The platform enables therapies that eliminate the need for cell harvesting, engineering, and preconditioning chemotherapy, simplifying treatment and reducing costs.

While promising, the deal involves risks such as regulatory hurdles, clinical trial uncertainties, and short-term financial strain from the acquisition cost, which could delay commercialization.

Positive interim data from the INVISE trial, expected late 2025, could speed up regulatory approval and adoption of in vivo CAR-T therapies.

Interius's lead candidate, INT2104, targets CD20-positive B-cell malignancies by reprogramming T and NK cells inside the patient’s body, representing a paradigm shift in CAR-T therapy.